vs

Side-by-side financial comparison of Linde plc (LIN) and Voyager Therapeutics, Inc. (VYGR). Click either name above to swap in a different company.

Voyager Therapeutics, Inc. is the larger business by last-quarter revenue ($15.3M vs $8.8M, roughly 1.7× Linde plc). On growth, Voyager Therapeutics, Inc. posted the faster year-over-year revenue change (144.3% vs 8.2%). Linde plc produced more free cash flow last quarter ($898.0K vs $-135.1M). Over the past eight quarters, Voyager Therapeutics, Inc.'s revenue compounded faster (-11.4% CAGR vs -96.7%).

Linde is a global multinational chemical company and the world's largest industrial gas supplier by market share and revenue. Founded by German scientist and engineer Carl von Linde in 1879 in Wiesbaden, Germany, the company is now headquartered in Woking, United Kingdom, and registered in Ireland as Linde plc. Linde plc was formed in 2018 through the merger of Linde AG and Praxair, which was founded in 1907 in the United States as Linde Air Products Company.

Voyager Therapeutics, Inc. is a clinical-stage biotechnology firm focused on developing AAV gene therapies for severe neurological diseases including Parkinson's, ALS, and rare monogenic CNS disorders. It operates mainly in the U.S., partnering with global biopharma companies to advance its treatment pipeline for underserved patient populations.

LIN vs VYGR — Head-to-Head

Bigger by revenue
VYGR
VYGR
1.7× larger
VYGR
$15.3M
$8.8M
LIN
Growing faster (revenue YoY)
VYGR
VYGR
+136.0% gap
VYGR
144.3%
8.2%
LIN
More free cash flow
LIN
LIN
$136.0M more FCF
LIN
$898.0K
$-135.1M
VYGR
Faster 2-yr revenue CAGR
VYGR
VYGR
Annualised
VYGR
-11.4%
-96.7%
LIN

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
LIN
LIN
VYGR
VYGR
Revenue
$8.8M
$15.3M
Net Profit
Gross Margin
48.5%
Operating Margin
27.8%
Net Margin
Revenue YoY
8.2%
144.3%
Net Profit YoY
20.5%
EPS (diluted)
$3.98

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LIN
LIN
VYGR
VYGR
Q1 26
$8.8M
Q4 25
$8.8B
$15.3M
Q3 25
$8.6B
$13.4M
Q2 25
$8.5B
$5.2M
Q1 25
$8.1B
$6.5M
Q4 24
$8.3B
$6.3M
Q3 24
$8.4B
$24.6M
Q2 24
$8.3B
$29.6M
Net Profit
LIN
LIN
VYGR
VYGR
Q1 26
Q4 25
$1.5B
Q3 25
$1.9B
$-27.9M
Q2 25
$1.8B
$-33.4M
Q1 25
$1.7B
$-31.0M
Q4 24
$1.7B
Q3 24
$1.6B
$-9.0M
Q2 24
$1.7B
$-10.1M
Gross Margin
LIN
LIN
VYGR
VYGR
Q1 26
48.5%
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Operating Margin
LIN
LIN
VYGR
VYGR
Q1 26
27.8%
Q4 25
23.0%
Q3 25
27.5%
-228.9%
Q2 25
27.7%
-704.3%
Q1 25
26.9%
-536.0%
Q4 24
27.4%
Q3 24
25.0%
-56.0%
Q2 24
26.4%
-50.8%
Net Margin
LIN
LIN
VYGR
VYGR
Q1 26
Q4 25
17.5%
Q3 25
22.4%
-208.7%
Q2 25
20.8%
-642.0%
Q1 25
20.6%
-479.2%
Q4 24
20.8%
Q3 24
18.5%
-36.7%
Q2 24
20.1%
-34.3%
EPS (diluted)
LIN
LIN
VYGR
VYGR
Q1 26
$3.98
Q4 25
$3.28
Q3 25
$4.09
$-0.47
Q2 25
$3.73
$-0.57
Q1 25
$3.51
$-0.53
Q4 24
$3.61
Q3 24
$3.22
$-0.16
Q2 24
$3.44
$-0.18

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LIN
LIN
VYGR
VYGR
Cash + ST InvestmentsLiquidity on hand
$4.0M
$196.4M
Total DebtLower is stronger
$24.7M
Stockholders' EquityBook value
$40.1M
$196.1M
Total Assets
$86.3M
$252.3M
Debt / EquityLower = less leverage
0.62×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LIN
LIN
VYGR
VYGR
Q1 26
$4.0M
Q4 25
$5.1B
$196.4M
Q3 25
$4.5B
$208.9M
Q2 25
$4.8B
$215.6M
Q1 25
$5.3B
$236.0M
Q4 24
$4.8B
$266.7M
Q3 24
$5.2B
$345.4M
Q2 24
$4.6B
$371.0M
Total Debt
LIN
LIN
VYGR
VYGR
Q1 26
$24.7M
Q4 25
$20.7B
Q3 25
$18.6B
Q2 25
$19.7B
Q1 25
$17.6B
Q4 24
$15.3B
Q3 24
$17.5B
Q2 24
$16.9B
Stockholders' Equity
LIN
LIN
VYGR
VYGR
Q1 26
$40.1M
Q4 25
$38.2B
$196.1M
Q3 25
$38.6B
$219.8M
Q2 25
$38.5B
$243.9M
Q1 25
$38.0B
$272.7M
Q4 24
$38.1B
$299.8M
Q3 24
$39.2B
$330.3M
Q2 24
$38.2B
$335.4M
Total Assets
LIN
LIN
VYGR
VYGR
Q1 26
$86.3M
Q4 25
$86.8B
$252.3M
Q3 25
$86.0B
$288.3M
Q2 25
$86.1B
$322.1M
Q1 25
$82.7B
$353.2M
Q4 24
$80.1B
$393.1M
Q3 24
$82.5B
$426.0M
Q2 24
$80.2B
$436.2M
Debt / Equity
LIN
LIN
VYGR
VYGR
Q1 26
0.62×
Q4 25
0.54×
Q3 25
0.48×
Q2 25
0.51×
Q1 25
0.46×
Q4 24
0.40×
Q3 24
0.45×
Q2 24
0.44×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LIN
LIN
VYGR
VYGR
Operating Cash FlowLast quarter
$-132.5M
Free Cash FlowOCF − Capex
$898.0K
$-135.1M
FCF MarginFCF / Revenue
10.2%
-880.7%
Capex IntensityCapex / Revenue
16.9%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$4.2B
$-239.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LIN
LIN
VYGR
VYGR
Q1 26
Q4 25
$3.0B
$-132.5M
Q3 25
$2.9B
$-31.0M
Q2 25
$2.2B
$-33.3M
Q1 25
$2.2B
$-37.9M
Q4 24
$2.8B
$-15.3M
Q3 24
$2.7B
$-28.0M
Q2 24
$1.9B
$-31.6M
Free Cash Flow
LIN
LIN
VYGR
VYGR
Q1 26
$898.0K
Q4 25
$1.6B
$-135.1M
Q3 25
$1.7B
$-31.3M
Q2 25
$954.0M
$-34.4M
Q1 25
$891.0M
$-38.6M
Q4 24
$1.6B
$-18.8M
Q3 24
$1.7B
$-28.2M
Q2 24
$796.0M
$-32.5M
FCF Margin
LIN
LIN
VYGR
VYGR
Q1 26
10.2%
Q4 25
17.9%
-880.7%
Q3 25
19.4%
-233.9%
Q2 25
11.2%
-660.9%
Q1 25
11.0%
-595.6%
Q4 24
18.8%
-300.0%
Q3 24
19.9%
-114.6%
Q2 24
9.6%
-110.0%
Capex Intensity
LIN
LIN
VYGR
VYGR
Q1 26
Q4 25
16.6%
16.9%
Q3 25
14.8%
1.5%
Q2 25
14.8%
21.3%
Q1 25
15.7%
10.2%
Q4 24
15.1%
56.1%
Q3 24
12.8%
1.0%
Q2 24
13.7%
3.3%
Cash Conversion
LIN
LIN
VYGR
VYGR
Q1 26
Q4 25
1.98×
Q3 25
1.53×
Q2 25
1.25×
Q1 25
1.29×
Q4 24
1.63×
Q3 24
1.76×
Q2 24
1.16×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons